Nit1-mediated signaling in T cells

T 细胞中 Nit1 介导的信号传导

基本信息

  • 批准号:
    7860298
  • 负责人:
  • 金额:
    $ 23.18万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-06-05 至 2012-11-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The mammalian Nit1 protein is homologous to bacterial and plant nitrilases. Previous studies have shown that Nit1 plays a role in wound and herbicide induced apoptosis. In flies and worms Nit1 is fused to the 5' end of the Fhit tumor suppressor. Therefore, it has been suggested that Nit1 may interact functionally with the Fhit pathway. The Fhit protein is a tumor suppressor. Somatic loss of Fhit is associated with a wide variety of cancers. Deletion of Fhit results in predisposition to spontaneous lymphoid malignancy in mice. There was also evidence showing that Nit1 deficiency lead to increased incidence of induced tumors in mice. The molecular mechanism involved in the tumor suppressing function of Fhit and Nit1 is not clear. Previous studies have shown that ectopic expression of Fhit or Nit1 can induce apoptosis in tumor cells, which requires caspase activation but is independent of Bcl-2 and Bcl-xL. Furthermore, Fhit- induced apoptosis can be inhibited by dominant negative mutant FADD. We and others have previously demonstrated that FADD is a mediator of the extrinsic apoptotic signaling pathways initiated by death receptors. Apoptosis induced by the Fas death receptor plays an important role in homeostasis in the immune system. To help understand the physiological function of Nit1 in T cells, we have performed preliminary analyses of Nit1 knockout mice. These mutant mice contained normal numbers of thymic and peripheral T cell sub populations. Our data showed that Nit1-/- T cells had a mild defect in Fas and Cainduced apoptosis. Although Nit1 may play a role in DNA-damage induced apoptosis in kidney cells, our preliminary data indicated that that apoptosis induced by a variety of stimuli including DNA damages due to 3- irradiation or chemical treatments was not affected in Nit1-deficient T cells. Unexpectedly, we found that Nit1 deficiency resulted in hyperproliferative responses in T cells induced through the antigen receptor stimulation. In this application, we propose an array of biochemical, genetic and immunological analyses to help understand the novel function of Nit1 in negatively regulating T cell proliferation. Specifically, our aims are (1) to analyze the function of Nit1 in T cell apoptosis; (2) to understand the non-apoptotic function of Nit1 in T cell proliferation; (3) to determine the functional domains of Nit1 by reverse genetics. PUBLIC HEALTH RELEVANCE: In this application, we describe a scientific plan to study the Nit1 protein which plays an essential role in immune system functions, and cancer. The results will facilitate the development of effective preventive and therapeutic approaches.
描述(由申请人提供):哺乳动物Nit1蛋白与细菌和植物硝化酶同源。以往的研究表明,Nit1在伤口和除草剂诱导的细胞凋亡中起作用。在苍蝇和蠕虫中,Nit1融合到Fhit肿瘤抑制子的5'端。因此,有人认为Nit1可能在功能上与Fhit通路相互作用。Fhit蛋白是一种肿瘤抑制因子。Fhit的体细胞丧失与多种癌症有关。Fhit的缺失导致小鼠自发性淋巴细胞恶性肿瘤的易感性。也有证据表明,Nit1缺乏导致小鼠诱导肿瘤的发生率增加。Fhit和Nit1抑制肿瘤的分子机制尚不清楚。先前的研究表明,Fhit或Nit1的异位表达可诱导肿瘤细胞凋亡,这需要caspase激活,但不依赖于Bcl-2和Bcl-xL。此外,Fhit诱导的细胞凋亡可以被显性阴性突变体FADD抑制。我们和其他人之前已经证明FADD是由死亡受体启动的外源性凋亡信号通路的介质。Fas死亡受体诱导的细胞凋亡在免疫系统稳态中起重要作用。为了帮助理解Nit1在T细胞中的生理功能,我们对Nit1敲除小鼠进行了初步分析。这些突变小鼠含有正常数量的胸腺和外周T细胞亚群。我们的数据显示,Nit1-/- T细胞有轻微的Fas缺陷,并引起细胞凋亡。虽然Nit1可能在DNA损伤诱导的肾细胞凋亡中发挥作用,但我们的初步数据表明,在Nit1缺失的T细胞中,多种刺激(包括3-辐照或化学处理导致的DNA损伤)诱导的细胞凋亡不受影响。出乎意料的是,我们发现Nit1缺乏导致抗原受体刺激诱导的T细胞超增殖反应。在这个应用中,我们提出了一系列的生化、遗传和免疫学分析来帮助理解Nit1在负调控T细胞增殖中的新功能。具体来说,我们的目标是:(1)分析Nit1在T细胞凋亡中的功能;(2)了解Nit1在T细胞增殖中的非凋亡功能;(3)通过反向遗传学确定Nit1的功能域。公共卫生相关性:在本申请中,我们描述了一个科学计划来研究在免疫系统功能和癌症中起重要作用的Nit1蛋白。研究结果将有助于开发有效的预防和治疗方法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JIANKE ZHANG其他文献

JIANKE ZHANG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JIANKE ZHANG', 18)}}的其他基金

Targeting RIP1-mediated pathways for immune homeostasis and tolerance
靶向 RIP1 介导的免疫稳态和耐受途径
  • 批准号:
    9113902
  • 财政年份:
    2016
  • 资助金额:
    $ 23.18万
  • 项目类别:
Targeting Daxx-mediated complex for autoimmune diseases
靶向 Daxx 介导的复合物治疗自身免疫性疾病
  • 批准号:
    8493108
  • 财政年份:
    2013
  • 资助金额:
    $ 23.18万
  • 项目类别:
Targeting Daxx-mediated complex for autoimmune diseases
靶向 Daxx 介导的复合物治疗自身免疫性疾病
  • 批准号:
    8728728
  • 财政年份:
    2013
  • 资助金额:
    $ 23.18万
  • 项目类别:
Flow Cytometry
流式细胞仪
  • 批准号:
    8302941
  • 财政年份:
    2011
  • 资助金额:
    $ 23.18万
  • 项目类别:
Flow Cytometry
流式细胞仪
  • 批准号:
    8084098
  • 财政年份:
    2010
  • 资助金额:
    $ 23.18万
  • 项目类别:
Nit1-mediated signaling in T cells
T 细胞中 Nit1 介导的信号传导
  • 批准号:
    7708394
  • 财政年份:
    2009
  • 资助金额:
    $ 23.18万
  • 项目类别:
The Function of cFLIP in B Lymphocytes
cFLIP 在 B 淋巴细胞中的功能
  • 批准号:
    7646458
  • 财政年份:
    2008
  • 资助金额:
    $ 23.18万
  • 项目类别:
The Function of cFLIP in B Lymphocytes
cFLIP 在 B 淋巴细胞中的功能
  • 批准号:
    7531980
  • 财政年份:
    2008
  • 资助金额:
    $ 23.18万
  • 项目类别:
Apoptosis and Proliferation Signaling Mediated by FADD
FADD 介导的细胞凋亡和增殖信号
  • 批准号:
    6928562
  • 财政年份:
    2002
  • 资助金额:
    $ 23.18万
  • 项目类别:
Apoptosis and Proliferation Signaling Mediated by FADD
FADD 介导的细胞凋亡和增殖信号
  • 批准号:
    6760990
  • 财政年份:
    2002
  • 资助金额:
    $ 23.18万
  • 项目类别:

相似海外基金

Development of back bone vectors for chimeric antigen receptors against key molecules, CD47 and CD24, activating macrophages
开发针对关键分子 CD47 和 CD24 的嵌合抗原受体的骨干载体,激活巨噬细胞
  • 批准号:
    23K06728
  • 财政年份:
    2023
  • 资助金额:
    $ 23.18万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Engineering synthetic adhesion receptors to enhance the sensitivity of therapeutic chimeric antigen receptors
工程合成粘附受体以增强治疗性嵌合抗原受体的敏感性
  • 批准号:
    MR/W031353/1
  • 财政年份:
    2022
  • 资助金额:
    $ 23.18万
  • 项目类别:
    Research Grant
CAREER: Engineering next-generation chimeric antigen receptors for cancer immunotherapy using phospho-proteomics
职业:利用磷酸蛋白质组学设计用于癌症免疫治疗的下一代嵌合抗原受体
  • 批准号:
    2145853
  • 财政年份:
    2022
  • 资助金额:
    $ 23.18万
  • 项目类别:
    Continuing Grant
Construction of a drug discovery platform utilizing antigen receptors that regulate the quality of cancer immunity
利用调节癌症免疫质量的抗原受体构建药物发现平台
  • 批准号:
    22K06603
  • 财政年份:
    2022
  • 资助金额:
    $ 23.18万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Modeling based design of chimeric antigen receptors for Natural Killer cell-based immunotherapy
用于基于自然杀伤细胞的免疫治疗的嵌合抗原受体的基于建模的设计
  • 批准号:
    10701754
  • 财政年份:
    2022
  • 资助金额:
    $ 23.18万
  • 项目类别:
Modeling based design of chimeric antigen receptors for Natural Killer cell-based immunotherapy
用于基于自然杀伤细胞的免疫治疗的嵌合抗原受体的基于建模的设计
  • 批准号:
    10557760
  • 财政年份:
    2022
  • 资助金额:
    $ 23.18万
  • 项目类别:
Molecualr imaging for development of chimeric antigen receptors (CARs) resistant to T cell exhaustion
用于开发抗 T 细胞耗竭的嵌合抗原受体 (CAR) 的分子成像
  • 批准号:
    20H03536
  • 财政年份:
    2020
  • 资助金额:
    $ 23.18万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Chimeric antigen receptors on regulatory T cells as a treatment strategy in auto-immune diseases.
调节性 T 细胞上的嵌合抗原受体作为自身免疫性疾病的治疗策略。
  • 批准号:
    437200
  • 财政年份:
    2020
  • 资助金额:
    $ 23.18万
  • 项目类别:
    Studentship Programs
Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery
通过干细胞递送治疗性抗 HIV 嵌合抗原受体
  • 批准号:
    10542442
  • 财政年份:
    2020
  • 资助金额:
    $ 23.18万
  • 项目类别:
Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery
通过干细胞递送治疗性抗 HIV 嵌合抗原受体
  • 批准号:
    9922602
  • 财政年份:
    2020
  • 资助金额:
    $ 23.18万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了